Supplemental table 1 Combined ORs for rs2981582 and each of the other investigated SNPs in the ORIGO cohort

		rs3803662 near TNRC9			
		0 (wt/wt) 1 (wt/mt) 2 (mt/mt)			
rs2981582 in FGFR2	0 (wt/wt)	1.00	1.25 (0.87-1.78)	1.12 (0.64-1.97)	
	1 (wt/mt)	1.28 (0.95-1.72)	1.48 (1.06-2.05)	1.90 (1.07-3.39)	
	2 (mt/mt)	1.76 (1.17-2.66)	2.22 (1.37-3.60)	1.35 (0.57-3.20)	

P-value for overall differences was p=0.022

		rs12443621 near TNRC9			
		0 (wt/wt) 1 (wt/mt) 2 (mt/mt)			
rs2981582 in FGFR2	0 (wt/wt)	1.00	1.14 (0.78-1.66)	1.14 (0.70-1.86)	
	1 (wt/mt)	1.26 (0.85-1.85)	1.44 (1.00-2.07)	1.65 (1.04-2.64)	
	2 (mt/mt)	2.12 (1.22-3.69)	2.04 (1.27-3.27)	1.33 (0.74-2.40)	

P-value for overall differences was p=0.018

		rs8051542 near TNRC9		
		0 (wt/wt)	1 (wt/mt)	1 (mt/mt)
rs2981582 in FGFR2	0 (wt/wt)	1.00	1.14 (0.76-1.71)	0.98 (0.61-1.57)
	1 (wt/mt)	1.34 (0.87-2.05)	1.40 (0.95-2.07)	1.20 (0.77-1.87)
	2 (mt/mt)	1.93 (1.07-3.47)	1.78 (1.09-2.91)	1.50 (0.80-2.79)

P-value for overall differences was p=0.124

		rs889312 near MAP3K1		
0 (wt/wt) 1 (wt/mt) 2 (n				2 (mt/mt)
rs2981582 in FGFR2	0 (wt/wt)	1.00	0.76 (0.54- 1.07)	0.73 (0.42-1.29)
	1 (wt/mt)	1.00 (0.73-1.37)	1.08 (0.79-1.47)	1.61 (0.93-2.80)
	2 (mt/mt)	1.25 (0.82-1.90)	1.64 (1.04-2.58)	1.63 (0.68-3.90)

P-value for overall differences was p=0.018

		rs13281615 on 8q24		
		0 (wt/wt)	1 (wt/mt)	2 (mt/mt)
2 in	0 (wt/wt)	1.00	1.12 (0.78-1.61)	1.10 (0.67-1.80)
rs2981582 FGFR2	1 (wt/mt)	1.28 (0.89-1.84)	1.48 (1.05-2.08)	1.33 (0.83-2.12)
	2 (mt/mt)	1.29 (0.79-2.11)	2.23 (1.39-3.57)	2.18 (1.17-4.05)

P-value for overall differences was p=0.018

		rs3817198 in LSP1		
		0 (wt/wt)	1 (wt/mt)	2 (mt/mt)
2 in	0 (wt/wt)	1.00	1.16 (0.82-1.63)	1.15 (0.64-2.04)
rs2981582 FGFR2	1 (wt/mt)	1.28 (0.94-1.74)	1.54 (1.12-2.12)	1.31 (0.79-2.17)
	2 (mt/mt)	1.85 (1.22-2.81)	1.92 (1.21-3.04)	1.37 (0.65-2.89)

P-value for overall differences was p=0.044

			rs889312 near MAP3K1		
		rs3803662 near TNRC9	0 (wt/wt)	1 (wt/mt)	2 (mt/mt)
	0 (wt/wt)	0 (wt/wt)	1.00	0.79 (0.49-1.30)	1.07 (0.48-2.38)
		1 (wt/mt)	1.26 (0.76-2.09)	1.11 (0.64-1.94)	0.66 (0.26-1.68)
R2		2 (mt/mt)	1.81 (0.77-4.27)	0.54 (0.21-1.37)	0.72 (0.15-3.32)
FGFR2	1 (wt/mt)	0 (wt/wt)	1.11 (0.72-1.72)	1.07 (0.69-1.64)	1.93 (0.89-4.20)
582 in		1 (wt/mt)	1.18 (0.72-1.93)	1.39 (0.85-2.27)	1.68 (0.71-3.98)
rs29815		2 (mt/mt)	1.12 (0.51-2.48)	2.22 (0.91-5.42)	5 cases
rs2	(mt/mt)	0 (wt/wt)	1.22 (0.69-2.15)	2.00 (1.03-3.88)	2.32 (0.63-8.52)
		1 (wt/mt)	1.90 (0.90-4.02)	2.19 (1.07-4.48)	1.79 (0.47-6.78)
	2	2 (mt/mt)	2.14 (0.58-7.94)	0.54 (0.15-1.94)	One case

P-value for overall differences was p=0.209

The combined effect on breast cancer risk of SNP rs2981582 and each one of the other six SNPs was explored pairwise in the ORIGO cohort. The observed odds ratios and their 95% confidence intervals are given in these tables.

Abbreviations: SNP, single nucleotide polymorphism; wt/wt, homozygotes for the wildtype allele; wt/mt, heterozygotes; mt/mt, homozygotes for the mutated allele.